ArticleBMC medicine2021
Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting.
Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Effectiveness ofThe Journal of international medical research · 2025Pooled it
- Reproductive Challenges in Mutated BRCA Gene Carriers: A Narrative Review.Current issues in molecular biology · 2026Review
- Sexual Health, Quality of Life, and Fertility Counselling in Breast Cancer Survivors Younger than 40 Years.Medicina (Kaunas, Lithuania) · 2026Article
- Roles of Goserelin in Gynecological Disorders.Drug design, development and therapy · 2026Review
- Breastfeeding after breast cancer in young BRCA carriers.Journal of the National Cancer Institute · 2025Observational
- Early breast cancer in youngTherapeutic advances in medical oncology · 2025Review
- Fertility and Pregnancy-Related Issues in YoungBreast cancer : basic and clinical research · 2024Review
- Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review.Open medicine (Warsaw, Poland) · 2024Article
- Preimplantation genetic testing for monogenic disorders: clinical experience with BRCA1 and BRCA2 from 2010-2021.Journal of assisted reproduction and genetics · 2023Article
- The Future of Breast Cancer Research in the Survivorship Field.Oncology and therapy · 2023Review
- Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women.Life (Basel, Switzerland) · 2023Article
- Reproductive and Obstetric Outcomes after Fertility-Sparing Treatments for Cervical Cancer: Current Approach and Future Directions.Journal of clinical medicine · 2023Review
- A Multi-Institutional Informed Consent Proposal as a Prevention Tool for Combined Oral Contraceptive Intake and Thrombotic Risk.Journal of personalized medicine · 2023Review
- Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis.World journal of surgical oncology · 2023Article
- Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Hormones (Athens, Greece) · 2023Review
- BRCA, infertility, and fertility preservation: a review for counseling.Journal of assisted reproduction and genetics · 2023Review
- Fertility Preservation in Endometrial Cancer-Treatment and Molecular Aspects.Medicina (Kaunas, Lithuania) · 2023Review
- The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.International journal of molecular sciences · 2023Review
- Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women?Infectious agents and cancer · 2022Article
- SARS-CoV-2 Vaccines and Adverse Effects in Gynecology and Obstetrics: The First Italian Retrospective Study.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealthy individuals and patients with cancer who are carriers of germline pathogenic variants in the BRCA1/2 genes face multiple reproductive challenges that require appropriate counseling and specific expertise. MAIN BODY: On December 5th-7th, 2019, patient advocates and physicians with expertise in the field of reproductive medicine, fertility preservation, and oncology were invited to "San Giuseppe Moscati" Hospital in Avellino (Italy) for a workshop on reproductive management of women with germline pathogenic variants in the BRCA1/2 genes. From the discussion regarding the current evidence and future prospective in the field, eight main research questions were formulated and eight recommendations were developed regarding fertility, fertility preservation, preimplantation genetic testing, and pregnancy in healthy carriers and patients with cancer.
conclusionSeveral misconceptions about the topic persist among health care providers and patients often resulting in a discontinuous and suboptimal management. With the aim to offer patient-tailored counseling about reproductive issues, both awareness of current evidences and research should be promoted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.